PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics

R. Altman,T. Klein,E. McDonagh,J. Callaghan,C. Thorn

DOI: https://doi.org/10.1097/FPC.0000000000000058

2014-09-01

Abstract:Disorders involving uric acid including gout, hyperuricemia and resultant kidney failure are prevalent. There are three main groups of pharmaceuticals used for modulating uric acid: 1. Drugs that reduce the generation of uric acid (allopurinol and febuxistat), 2. Those that increase the removal of uric acid (rasburicase, pegloticase), (both depicted in Figure 1) or 3. Those that inhibit the reabsorption of uric acid (depicted in Figure 3). This summary briefly describes the mechanisms of action and the candidate genes and genetic variants associated with response to these drugs. Clinically relevant genetic variants have been identified for allopurinol and rasburicase, and CPIC guidelines have been published that recommend selection of alternative treatments for some individuals. A more extensive description and interactive version can be found for each pathway at www.pharmgkb.org. Figure 1 Uric acid-lowering drugs pathway, Pharmacodynamics Figure 3 Uricosurics pathway, Pharmacodynamics 1) Drugs that reduce the generation of uric acid: allopurinol and febuxostat Pharmacodynamics Allopurinol is a drug indicated for the treatment of gout, prophylaxis of hyperuricemia in patients undergoing chemotherapy, and prevention of kidney stones recurrence [1]. Allopurinol and its metabolite oxypurinol are analogues of hypoxanthine and xanthine, respectively, and work by binding to and inhibiting xanthine dehydrogenase (XDH), preventing the formation of uric acid (Figure 1) [1–5]. Hypoxanthine and xanthine are cleared in the urine or reutilized in the synthesis of nucleotides and nucleic acids [1, 6]. Febuxostat (Uloric®) is a non-purine inhibitor of XDH that can bind to and inhibit both oxidized or reduced forms of XDH (Figure 1) [2, 7, 8]. It is indicated for the treatment of hyperuricemia in patients with gout (but not for asymptomatic hyperuricemia) [9], and is an alternative therapy for patients where allopurinol has been contraindicated due to allergic responses [7, 8, 10]. A downside to allopurinol/febuxostat treatment is that existing high levels of plasma uric acid are not cleared and, as xanthine is less soluble than uric acid, xanthine kidney stones or xanthine nephropathy may result [3, 6].

Chemistry,Medicine